ASSOCIATION OF SERUM FERRITIN AND CRP LEVELS WITH DEVELOPMENT AND SEVERITY OF DIABETIC RETINOPATHY
Background: Diabetes mellitus is a global health issue. Chronic hyperglycaemia induces endothelial dysfunction and metabolic derangements which are postulated to be the cornerstone for the pathogenesis of diabetic microangiopathic complications. The interplay of oxidative stress, endothelial dysfunction and inflammation in this regard has led to investigation of role of inflammatory biomarkers as adjuncts to routine diagnostic testing. This study was designed to elucidate the association between serum ferritin and high sensitivity CRP levels and diabetic retinopathy. Methods: The study was carried out at Department of Physiology and Centre for Research in Experimental and Applied Medicine (CREAM), Army Medical College, in collaboration with Armed Forces Institute of Ophthalmology, Rawalpindi for a period of one year. A total of 90 subjects were recruited into three equal groups; healthy subjects, diabetics and patients with diabetic retinopathy. Serum high sensitivity C-reactive protein (hs-CRP) was estimated by Enzyme Immunoassay (EIA) and serum ferritin levels were carried out by enzyme linked immunosorbent assay. Results: The mean age was 48.50±5.32, 50.90±3.83 and 50.83±3.54 years respectively. Insignificant differences in height, weight and BMI were found across the groups. Highly significant difference was noted in the mean CRP levels in normal subjects. The mean ferritin levels were also found to be significantly different. Univariate multinomial regression revealed that variance in CRP levels could account for 91.1% of variance in status of patients and that in ferritin levels could account for 96.7%. Conclusion: These prognostic markers correlate well with diabetic retinopathy and have an independent predictive ability as well. This may in future be inculcated into screening and surveillance of diabetic microangiopathic complications.
Pak J Physiol 2017;13(4):11–3
2. Guillausseau P, Laloi-Michelin M. Pathogenesis of type 2 diabetes mellitus. Rev Med Interne 2003;24(11):730–7.
3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–12.
4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047–53.
5. Jamal-u-Din, Qureshi MB, Khan AJ, Khan MD, Ahmad K. Prevalence of diabetic retinopathy among individuals screened positive for diabetes in five community-based eye camps in northern Karachi, Pakistan. J Ayub Med Coll Abbottabad 2006;18(3):40–3.
6. Hayat AS, Khan AH, Baloch GH, Sheikh N. Frequency and pattern of retinopathy in newly diagnosed type 2 diabetic patients at tertiary care settings in Abbottabad. J Ayub Med Coll Abbottabad 2012;24(2):87–9.
7. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105(16):1890–6.
8. Crawford TN, Alfaro I, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev 2009;5(1):8–13.
9. van Hecke M, Dekker J, Nijpels G, Moll A, Heine R, Bouter L, et al. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia 2005;48(7):1300–6.
10. Fu CC, Wu DA, Wang JH, Yang WC, Tseng CH. Association of C-reactive protein and hyperuricemia with diabetic nephropathy in Chinese type 2 diabetic patients. Acta Diabetol 2009;46(2):127–34.
11. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes —the EURODIAB Prospective Complications Study. Diabetologia 2005;48:370–8.
12. Torzewski M, Rist C, Mortensen RF, Zwaka TP, Bienek M, Waltenberger J, et al. C-reactive protein in the arterial intima role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol 2000;20(9):2094–9.
13. Harned J, Ferrell J, Lall MM, Fleisher LN, Nagar S, Goralska M, et al. Altered ferritin subunit composition: change in iron metabolism in lens epithelial cells and downstream effects on glutathione levels and VEGF secretion. Invest Ophthalmol Vis Sci 2010;51:4437–46.
14. Wilson JG, Lindquist JH, Grambow SC, Crook ED, Maher JF. Potential role of increased iron stores in diabetes. Am J Med Sci 2003;325:332–9.
15. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: past, present and future. Biochim Biophys Acta 2010;1800(8):760–9.
16. Larsen M, Godt J, Larsen N, Lund-Andersen H, Sjølie AK, Agardh E, et al. Automated detection of fundus photographic red lesions in diabetic retinopathy. Invest Ophthalmol Vis Sci 2003;44(2):761–6.
17. Acton RT, Barton JC, Passmore LV, Adams PC, Speechley MR, Dawkins FW, et al. Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care 2006;29:2084–9.
18. Izuora KE, Chase HP, Jackson WE, Coll JR, Osberg IM, Gottlieb PA, et al. Inflammatory markers and diabetic retinopathy in type 1 diabetes. Diabetes Care 2005;28:714–5.
19. Peng D, Wang J, Zhang R, Tang S, Jiang F, Chen M, et al. C-reactive protein genetic variant is associated with diabetic retinopathy in Chinese patients with type 2 diabetes. BMC Endocr Disord 2015;15:8.
20. Blum A, Socea D, Ben-Shushan RS, Keinan-Boker L, Naftali M, Segol G, et al. A decrease in VEGF and inflammatory markers is associated with diabetic proliferative retinopathy. Eur Cytokine Netw 2012;23(4):158–62.
21. Budak YU, Akdogan M, Huysal K. Relationship of PON1 activity and hsCRP concentration with disease status in patients with type 2 diabetes mellitus with and without retinopathy. Int J Diabetes Developing Countries 2013;33:40–5.
22. Jia Z, Liu C, Li H. Changes of the concentration of serum ischemia modified albumin and high sensitivity C-reactive protein in type 2 diabetic patients with retinopathy. Zhonghua Yan Ke Za Zhi 2009;45:805–8. [Article in Chinese]
23. Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000;23(12):1835–9.
24. Sen D, Ghosh S, Roy D. Correlation of C-reactive protein and body mass index with diabetic retinopathy in Indian population. Diabetes Metab Syndr 2015;9(1):28–9.
25. Canturk Z, Çetinarslan B, Tarkun İ, Zafer Canturk NZ. Serum ferritin levels in poorly- and well-controlled diabetes mellitus. Endocr Res 2003;29:299–306.